menu
    • menu
    [{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Funding","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ National Institutes of Health","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ National Institutes of Health"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aqualung Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"ALT-100","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Aqualung Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aqualung Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Aqualung Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Aqualung Therapeutics

    Menu

    Aqualung Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aqualung Therapeutics Gets NIH Approval to Advance to IND-Enabling Studies for Development of Novel Antibody f...

                            Details : Aqualung has begun IND-enabling pharmaco-dynamic, pharmacokinetic and toxicology studies that will advance their lead therapeutic ALT-100 into human studies to treat Acute Respiratory Distress Syndrome (ARDS).

                            Product Name : ALT-100

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 27, 2020

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aqualung Therapeutics Advances Its Investigational Monoclonal Antibody into IND-Enabling Studies

                            Details : Aqualung Therapeutics Corporation is developing ALT-100 to reduce the mortality of Acute Respiratory Distress Syndrome (ARDS) and Ventilator-Induced Lung Injury (VILI).

                            Product Name : ALT-100

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            March 18, 2020

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Aqualung Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Aqualung Therapeutics Gets $2.3 M NIH Fast-Track Award To Develop Novel Therapeutic Antibody For Patients With...

                            Details : The funding is based on the company's progress in completion of the initial Fastrack Phase I studies of its novel immune-based anti-inflammatory therapeutic antibody for critically ill patients with acute lung injury.

                            Product Name : ALT-100

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            February 06, 2020

                            Lead Product(s) : ALT-100

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : National Institutes of Health

                            Deal Size : $2.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth